Amendment No. #2 to SC13-D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 2)

 

 

Synbiotics Corporation

(Name of Issuer)

 

 

Common Stock

(Title of Class of Securities)

 

 

871566105

(CUSIP Number)

 

 

Paul A. Rosinack

15817 Caminito Cantaras

Del Mar, California 92014

(858) 794-7075

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

 

October 9, 2003

(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.

 

(Continued on the following pages)

CUSIP No. 871566105

  1

   

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Paul A Rosinack

  2

   

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ¨

(b)  ¨

  3

   

SEC USE ONLY

 

  4

   

SOURCE OF FUNDS

 

PF

  5

   

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO

ITEM 2(d) or 2(e)

  ¨

 

  6

   

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

   

  7

 

   

        SOLE VOTING POWER

 

        1,000,000

     8   

        SHARED VOTING POWER

 

 

 
     9   

        SOLE DISPOSITIVE POWER

 

        1,000,000

 
  

10

   

        SHARED DISPOSITIVE POWER

 

 

11

   

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,000,000

12

   

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

   ¨

 

13

   

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

4.9%

14

   

TYPE OF REPORTING PERSON

 

IN

 

-2-

Item 1.    Security and Issuer.

 

This Schedule 13D relates to the Common Stock of Synbiotics Corporation, a California corporation. Synbiotics’ principal executive offices are located at 11011 Via Frontera, San Diego, California 92127.

 

Item 2.    Identity and Background.

 

Paul A Rosinack, a citizen of the United States, whose residence is located at 15817 Caminito Cantaras Del Mar, CA 92014, was an employee of Synbiotics since October 1996, and most recently held the position of President, Chief Executive Officer and Director until his resignation from Synbiotics on September 24, 2002. During the past five years, Mr. Rosinack has not been convicted in a criminal proceeding, excluding traffic violations or similar misdemeanors, nor has he been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in Mr. Rosinack being at any time subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Item 3.    Source and Amount of Funds or Other Consideration.

 

Not applicable.

 

Item 4.    Purpose of Transaction.

 

On October 9, 2003, Mr. Rosinack sold 49,690 shares of common stock of Synbiotics Corporation in the open market at an average selling price of $0.17 per share. The transaction was effected through Mr. Rosinack’s personal stock broker on the NASD over-the-counter bulletin board. The proceeds received from the sale will be used by Mr. Rosinack for his own personal funds. As a result of the sale of the shares, Mr. Rosinack’s beneficial ownership was reduced below 5%. Mr. Rosinack does not intend to be other than a passive investor in Synbiotics Corporation.

 

Item 5.    Interest in Securities of Issuer.

 

(a)   Mr. Rosinack presently beneficially owns 1,000,000 shares of Synbiotics Corporation common stock, which he believes constitutes approximately 4.9% of the Synbiotics Corporation’s common stock outstanding.

 

(b)   Mr. Rosinack has the sole power to vote and dispose of the 1,000,000 shares of Synbiotics Corporation common stock as identified in subparagraph (a) above.

 

(c)   In addition to the sale on October 9, 2003, discussed in Item 4, as previously reported on Schedule 13D dated September 16, 2003, during the period June 11, 2003 through September 19, 2003, Mr. Rosinack sold 257,000 shares of common stock of Synbiotics Corporation in the open market at an average selling price of $0.176 per share. The transactions were effected through Mr. Rosinack’s personal stock broker on the NASD over-the-counter bulletin board.

 

(d)   No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Mr. Rosinack’s shares of Synbiotics Corporation common stock.

 

(e)   Mr. Rosinack ceased to be the beneficial owner of more than 5% of Synbiotics Corporation common stock on October 9, 2003.

 

Item 6.    Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer.

 

None.

 

Item 7.    Material to be filed as Exhibits.

 

None.

 

-3-

SIGNATURE

 

After reasonable inquiry and to the best of each of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

 

October 16, 2003

Date

 

/s/    Paul A. Rosinack      

Signature

 

Paul A. Rosinack              

Name

 

-4-